Liquid biopsy genotyping in lung cancer: Ready for clinical utility?

Wei Lun Huang, Yi Lin Chen, Szu Chun Yang, Chung Liang Ho, Fang Wei, David T. Wong, Wu Chou Su, Chien Chung Lin

研究成果: Article

23 引文 (Scopus)

摘要

Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy.

原文English
頁(從 - 到)18590-18608
頁數19
期刊Oncotarget
8
發行號11
DOIs
出版狀態Published - 2017 一月 1

指紋

Epidermal Growth Factor Receptor
Lung Neoplasms
Biopsy
DNA
Hematologic Tests
Oncogenes
Saliva
Protein-Tyrosine Kinases
Neoplasms
Genotype
Urine
Technology
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

引用此文

@article{8d563bf0d0594c3cb3a8262e769c0836,
title = "Liquid biopsy genotyping in lung cancer: Ready for clinical utility?",
abstract = "Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy.",
author = "Huang, {Wei Lun} and Chen, {Yi Lin} and Yang, {Szu Chun} and Ho, {Chung Liang} and Fang Wei and Wong, {David T.} and Su, {Wu Chou} and Lin, {Chien Chung}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14613",
language = "English",
volume = "8",
pages = "18590--18608",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

Liquid biopsy genotyping in lung cancer : Ready for clinical utility? / Huang, Wei Lun; Chen, Yi Lin; Yang, Szu Chun; Ho, Chung Liang; Wei, Fang; Wong, David T.; Su, Wu Chou; Lin, Chien Chung.

於: Oncotarget, 卷 8, 編號 11, 01.01.2017, p. 18590-18608.

研究成果: Article

TY - JOUR

T1 - Liquid biopsy genotyping in lung cancer

T2 - Ready for clinical utility?

AU - Huang, Wei Lun

AU - Chen, Yi Lin

AU - Yang, Szu Chun

AU - Ho, Chung Liang

AU - Wei, Fang

AU - Wong, David T.

AU - Su, Wu Chou

AU - Lin, Chien Chung

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy.

AB - Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy.

UR - http://www.scopus.com/inward/record.url?scp=85015222262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015222262&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14613

DO - 10.18632/oncotarget.14613

M3 - Article

AN - SCOPUS:85015222262

VL - 8

SP - 18590

EP - 18608

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -